Accel Wealth Management Buys 60 Shares of Eli Lilly and Company (NYSE:LLY)

Accel Wealth Management lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 7.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 884 shares of the company’s stock after purchasing an additional 60 shares during the period. Accel Wealth Management’s holdings in Eli Lilly and Company were worth $515,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Fairfield Bush & CO. bought a new stake in Eli Lilly and Company in the 1st quarter valued at $107,000. Roundview Capital LLC lifted its stake in shares of Eli Lilly and Company by 2.6% during the 1st quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock worth $589,000 after buying an additional 53 shares during the last quarter. Merit Financial Group LLC bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth about $210,000. NewEdge Advisors LLC grew its stake in Eli Lilly and Company by 9.9% in the 1st quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock valued at $15,193,000 after buying an additional 4,774 shares during the last quarter. Finally, Barometer Capital Management Inc. bought a new stake in shares of Eli Lilly and Company during the first quarter worth approximately $561,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.5 %

NYSE:LLY traded up $3.79 during mid-day trading on Wednesday, hitting $778.69. 2,297,294 shares of the company’s stock were exchanged, compared to its average volume of 3,236,753. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a fifty-two week low of $334.58 and a fifty-two week high of $800.78. The company has a 50 day simple moving average of $727.96 and a 200-day simple moving average of $636.01. The firm has a market capitalization of $739.88 billion, a P/E ratio of 134.26, a PEG ratio of 1.70 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The company had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.09 earnings per share. As a group, research analysts expect that Eli Lilly and Company will post 12.42 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Bank of America raised their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. BMO Capital Markets raised their price objective on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Finally, Morgan Stanley increased their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $689.52.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 34,538 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $631.81, for a total transaction of $21,821,453.78. Following the completion of the transaction, the insider now directly owns 99,719,884 shares in the company, valued at $63,004,019,910.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders sold 195,055 shares of company stock valued at $125,254,657. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.